"AVERT Device Cuts Contrast-Agent Use at PCI, Renal Benefit Unsure" - Marlene Busko
In the AVERT trial of close to 600 patients who underwent coronary angiography and were at high risk of contrast-induced acute kidney injury (AKI), the studied device successfully reduced the volume of contrast agent by 15.5%, but this did not translate into a lower risk of kidney damage. Roxana Mehran, MD, a professor of cardiology at the Icahn School of Medicine at Mount Sinai presented these findings at the Society for Cardiac Angiography and Interventions (SCAI) 2016 Scientific Sessions. "AVERT was a very large study and was very successful in reducing the volume of contrast dye; however, the trial showed that maybe you need more reduction, because 15% wasn't enough to reduce contrast-induced acute kidney injury in these high-risk patients," said Dr. Mehran.
- Roxana Mehran, MD, Professor, Medicine, Cardiology, Population Science and Health Policy, Director, Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai
Learn more
Coronary Stent Patients May Not Need Long-Term Aspirin
Sep 26, 2019 View All Press Releases